Short-term Antiviral Activity of TMC278 - a Novel NNRTI - in Treatment-Naive HIV-1-Infected Subjects

TMC278 is being evaluated as a once-daily NNRTI for use in HIV-infected persons, including those infected with NNRTI-resistant HIV.

Continue to Short-term Antiviral Activity of TMC278 - a Novel NNRTI - in Treatment-Naive HIV-1-Infected Subjects on Medscape Headlines.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz